Key statistics dashboard for Jupiter Neurosciences, Inc. (JUNS). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues.
Stock Data
| Price | $2.93 |
| Market Cap | $1M |
| Beta | 2.78 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.16 |
| Price / Book | -4.59 |
| P/S | 22.55 |
| P/FCF | -0.20 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 88.34% |
| EBIT Margin | -14662.59% |
| EBITDA Margin | -14662.59% |
| Operating Margin | -15166.68% |
| Net Margin | -14220.12% |
Financial Health
| Current Ratio | 0.66 |
| Quick Ratio | 0.62 |
| Cash Ratio | 0.39 |
| Debt / Equity | -4.78 |
| Debt / Assets | 47.04% |
| Interest Coverage | -47.42 |
Per-Share Data
| Revenue per share | 0.12 |
| Book Value per share | -0.66 |
| Cash per share | 2.73 |
| FCF per share | -13.00 |
| Tangible Book Value per share | -0.66 |
| Dividend per share | 0.00 |
Related companies: ABVC · ALGS · FGEN · GNTA · GRCE · KZR · MRSN
Explore sector: Healthcare · Biotechnology
More sections of JUNS: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks